The sharp edge of immunosuppressive treatments: infections
Infection rates were higher in the anakinra group, especially the pneumonia and BSI rates were higher than in the tocilizumab group. The 30-day mortality rates were higher in patients who had an infection, especially in the tocilizumab group. This is one of the rare studies that evaluated infections developing in patients treated with anakinra and tocilizumab together.
Authors
- Melih Gaffar Gözükara (ORCID: https://orcid.org/0000-0002-6147-4053)
- Sudem Mahmutoğlu Çolak (ORCID: https://orcid.org/0000-0001-7214-2305)
- Uğur Kostakoğlu (ORCID: https://orcid.org/0000-0002-4589-0962)
- Ayşe Ertürk (ORCID: https://orcid.org/0000-0001-6413-9165)
- Tuba İlgar (ORCID: https://orcid.org/0000-0003-2476-8295)
- Kübra Akyüz (ORCID: https://orcid.org/0000-0002-4952-1689)
- Aybegüm Özşahin (ORCID: https://orcid.org/0000-0003-4500-8594)
- İlknur Esen Yıldız (ORCID: https://orcid.org/0000-0003-2987-0483)
Institutions
- Office of Infectious Diseases (US)
Publication Details
- Journal
- TURKISH JOURNAL OF MEDICAL SCIENCES
- Published
- 2024-08-23
- DOI
- https://doi.org/10.55730/1300-0144.5845
- Primary Topic
- Cytomegalovirus and herpesvirus research
- Type
- article
- Field-Weighted Citation Impact
- 0.00